Long-term medication guide for rasagiline: analyzing its safety and applicability

Rasagiline is one of the first-line treatments for Parkinson's disease and usually needs to be taken long-term. Clinical studies have shown that rasagiline can not only improve motor symptoms in patients with Parkinson's disease, but may also have neuroprotective effects and help delay disease progression. Its safety for long-term use has been verified in multiple studies, and many patients still maintain good efficacy after taking it for several years.

From the perspective of long-term use, rasagiline is well tolerated. Common adverse reactions include headache, joint pain, hypotension, dry mouth, nausea and mild anxiety, etc., which usually do not affect the continued use of the drug. However, for patients taking other dopaminergic drugs, long-term combined use may increase the risk of impulse control disorders (such as gambling, shopping addiction, etc.) or hallucinations, and therefore require regular evaluation by a physician.

In addition, since rasagiline is aMAO-B inhibitor, large amounts of food with high tyramine content (such as aged cheese, cured meats, red wine, etc.) should be avoided during long-term use to prevent rare but potentially serious hypertensive crises. In addition, certain antidepressants (such as SSRIs, SNRIs) combined with rasagiline may cause serotonin syndrome, so during long-term medication, patients need to inform their doctors about all medications they are taking to avoid the risk of drug interactions.

Overall, rasagiline is a Parkinson's disease drug suitable for long-term use, especially for patients early in the course of the disease or who are more effective when used alone. During long-term medication, patients should be followed up regularly to monitor efficacy and side effects, and adjust dosage or combination medication under the guidance of a doctor to ensure maximum treatment effect.

Reference materials:https://www.azilect.com/